Daré Bioscience, Inc. (DARE)
| Market Cap | 18.67M |
| Revenue (ttm) | 25,909 |
| Net Income (ttm) | -1.68M |
| Shares Out | 8.85M |
| EPS (ttm) | -0.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 216,743 |
| Open | 2.020 |
| Previous Close | 2.030 |
| Day's Range | 2.020 - 2.130 |
| 52-Week Range | 1.830 - 9.190 |
| Beta | 1.11 |
| Analysts | Strong Buy |
| Price Target | 12.50 (+492.42%) |
| Earnings Date | Aug 14, 2025 |
About DARE
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor sympto... [Read more]
Financial Performance
In 2024, Daré Bioscience's revenue was $9,784, a decrease of -99.65% compared to the previous year's $2.81 million. Losses were -$4.05 million, -86.56% less than in 2023.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for DARE stock is "Strong Buy." The 12-month stock price target is $12.5, which is an increase of 492.42% from the latest price.
News
Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and rea...
Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream
A first-of-its-kind solution for women's arousal in a proprietary topical formulation demonstrated to work where women need it most
UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar
A first-of-its-kind solution for women's arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most
Crude Oil Moves Lower; Daré Bioscience Shares Jump
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 0.4% on Monday.
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive
Interim Phase 3 Results Support Ovaprene's Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive Interim Phase 3 Results Support Ovaprene's Differentiation as a Firs...
Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders
Exploring Strategic Partnerships to Expand Platform Beyond Reproductive Health Exploring Strategic Partnerships to Expand Platform Beyond Reproductive Health
Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders
SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today ...
Daré Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript
Daré Bioscience, Inc. (NASDAQ:DARE) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants MarDee Haring-Layton - Chief Accounting Officer Sabrina Martucci Johnson - President ...
Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update
In addition to its proprietary Sildenafil Cream formulation, Daré is taking action to make three other solutions for women available commercially, two vaginal probiotics in 2025 and its proprietary mo...
Daré Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript
Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants MarDee Haring-Layton - Chief Accounting Officer Sabrina Martucci Johnson - Presiden...
Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update
With increasing demand for needed treatments designed for women, Daré is taking action to make its proprietary Sildenafil Cream formulation available via prescription this year With increasing demand ...
Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and well-being of women, will host a conference call and live webcast at 4:30...
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development
DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management
Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference
The panel will discuss the value proposition for investing in women's health. J.P. Morgan is hosting a three-panel women's health series at this year's conference to highlight the importance of innova...
Daré Bioscience, Inc. (DARE) Q3 2024 Earnings Call Transcript
Daré Bioscience, Inc. (NASDAQ:DARE) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants MarDee Haring-Layton - CAO Sabrina Martucci Johnson - President and CEO Conferen...
Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update
Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate – pivotal Phase 3 contra...
Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, will host a conference call and live webcast at 4:30 p...
Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health
DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management.
Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC
Provides Daré access to capital at Daré's discretion with any proceeds available to help fund portfolio advancement, such as the Phase 3 program for Sildenafil Cream, 3.6%, a potential first-in-catego...
Daré Bioscience, Inc. (DARE) Q2 2024 Earnings Call Transcript
Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2024 Earnings Call Transcript August 12, 2024 4:30 PM ET Company Participants MarDee Haring-Layton - CAO Sabrina Martucci Johnson - President and CEO Conference...
Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update
Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 con...
Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule
SAN DIEGO, July 19, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, announced that it was notified by the Nasdaq Office of...
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors
Ken Gayron to Step Down as a Member of the Company's Board Encinitas, California--(Newsfile Corp. - July 1, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announce...
Daré Bioscience Announces Reverse Stock Split
Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and we...
Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript
Daré Bioscience, Inc. (NASDAQ:DARE) Q1 2024 Earnings Call Transcript May 14, 2024 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO MarDee Haring-Layton - Chief Accounting ...